18F-FDG PET/CT代谢参数联合血清FOXM1在诊断结直肠癌淋巴结转移中的应用

doi:10.7517/issn.1674-0475.220717

摘要/Abstract

摘要： 本研究探讨¹⁸F-氟代脱氧葡萄糖(FDG)正电子发射/计算机断层显像(PET/CT)代谢参数联合血清叉头盒蛋白M1(FOXM1)诊断结直肠癌淋巴结转移的价值。共纳入103例结直肠癌患者进行研究,通过病理学检查确诊是否发生淋巴结转移,然后将患者分为转移组(51例)和非转移组(52例)。所有患者均进行¹⁸F-FDG PET/CT检查,获取最大标准化摄取值(SUVmax)、糖酵解总量(TLG)和肿瘤代谢体积(MTV)三项代谢参数。此外,通过ELISA法检测患者血清FOXM1水平。结果显示,非转移组的SUVmax显著高于转移组(P<0.001)。非转移组的MTV、TLG显著低于转移组(P<0.001)。非转移组的血清FOXM1显著低于转移组(P<0.001)。血清FOXM1与SUVmax显著负相关(P<0.01),而与MTV和TLG显著正相关(P<0.01)。SUVmax+MTV+TLG+血清FOXM1诊断淋巴结转移的AUC(0.974)和敏感性(92.16%)高于¹⁸F-FDG PET/CT代谢参数和血清FOXM1的单独诊断,特异性(94.23%)仅低于TLG单独诊断。¹⁸F-FDG PET/CT三项代谢参数(SUVmax、MTV及TLG)联合血清FOXM1诊断淋巴结转移的价值较高。

关键词: 结直肠癌, ¹⁸F-FDG PET/CT, 代谢参数, 叉头盒蛋白M1, 淋巴结转移

Abstract: This study investigated the value of ¹⁸F-fluorodeoxyglucose (FDG) positron emission/computed tomography (PET/CT) metabolic parameters combined with serum forkhead box protein M1 (FOXM1) in the diagnosis of lymph node metastasis of colorectal cancer. A total of 103 patients with colorectal cancer were included in this study, and the lymph node metastasis was confirmed by pathological examination, and then the patients were divided into the metastasis group (51 cases) and the non-metastasis group (52 cases). All patients underwent ¹⁸F-FDG PET/CT examination, and then three metabolic parameters of maximum normalized uptake value (SUVmax), total glycolysis (TLG) and tumor metabolic volume (MTV) were obtained. In addition, serum FOXM1 levels of patients were detected by the ELISA method. The results showed that the SUVmax of non-metastasis was significantly higher than that of metastasis group (P<0.001). The MTV and TLG of the non-metastatic group was significantly lower than that of the metastatic group (P<0.001). Serum FOXM1 in the non-metastatic group was significantly lower than that in the metastatic group (P<0.001). Serum FOXM1 was significantly negatively correlated with SUVmax (P<0.01), while significantly positively correlated with MTV and TLG (P<0.01). The AUC (0.974) and sensitivity (92.16%) of SUVmax+MTV+TLG+serum FOXM1 in the diagnosis of lymph node metastasis were higher than those of ¹⁸F-FDG PET/CT metabolic parameters and serum FOXM1 alone, and the specificity (94.23%) was only lower than that of TLG alone. The three metabolic parameters (SUVmax, MTV and TLG) of ¹⁸F-FDG PET/CT combined with serum FOXM1 have high value in the diagnosis of lymph node metastasis.

Key words: colorectal cancer, ¹⁸F-FDG PET/CT, metabolic parameters, forkhead box protein M1, lymph node metastasis

王萍, 谢丽璇. ¹⁸F-FDG PET/CT代谢参数联合血清FOXM1在诊断结直肠癌淋巴结转移中的应用[J]. 影像科学与光化学, 2022, 40(6): 1570-1575.

WANF Ping, XIE Lixuan. Application of ¹⁸F-FDG PET/CT Metabolic Parameters Combined with Serum FOXM1 in the Diagnosis of Lymph Node Metastasis in Colorectal Cancer[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(6): 1570-1575.

参考文献

[1] Gu M J, Huang Q C, Bao C Z, et al. Attributable causes of colorectal cancer in China[J]. BMC Cancer, 2018, 18(1):38.
[2] Arriola E, Navarro M, Parés D, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer[J]. Diseases of the Colon and Rectum, 2006, 49(4):478-484.
[3] Guney I B, Teke Z, Kucuker K A, et al. A prospective comparative study of contrast-enhanced CT, contrast-enhanced MRI and ¹⁸F-FDG PET/CT in the preoperative staging of colorectal cancer patients[J]. Annali Italiani di Chirurgia, 2020, 91:658-667.
[4] Lee D H, Lee J M. Whole-body PET/MRI for colorectal cancer staging:Is it the way forward?[J]. Journal of Magnetic Resonance Imaging, 2017, 45(1):21-35.
[5] Tsili A C, Alexiou G, Naka C, et al. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT:A meta-analysis[J]. Acta Radiologica:Stockholm, Sweden:1987, 2021, 62(3):302-312.
[6] Caresia Aroztegui A P, García Vicente A M, Alvarez Ruiz S, et al. ¹⁸F-FDG PET/CT in breast cancer:Evidence-based recommendations in initial staging[J]. Tumour Biology, 2017, 39(10):1010428317728285.
[7] Castello A, Rossi S, Lopci E. ¹⁸F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer:State of the art[J]. Current Radiopharmaceuticals, 2020, 13(3):228-237.
[8] Paydary K, Seraj S M, Zadeh M Z, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer[J]. Molecular Imaging and Biology, 2019, 21(1):1-10.
[9] 黄慧. ¹⁸F-FDG PET/CT显像在结直肠癌术后复发中的应用价值[D]. 天津:天津医科大学, 2015.
[10] 田蓉蓉, 薄云峰, 张毅勋, 等. ¹⁸F-FDG PET/CT术前诊断结直肠癌区域淋巴结转移的价值[J]. 中国医学影像学杂志, 2017, 25(11):801-806.
[11] 王大龙, 于丽娟, 田墨涵, 等. ¹⁸F-FDG PET/CT显像在结直肠癌术前分期中的价值[J]. 临床放射学杂志, 2012, 31(1):70-74.
[12] Gartel A L. FOXM1 in cancer:Interactions and vulnerabilities[J]. Cancer Research, 2017, 77(12):3135-3139.
[13] Liao G B, Li X Z, Zeng S, et al. Regulation of the master regulator FOXM1 in cancer[J]. Cell Communication and Signaling, 2018, 16(1):57.
[14] Yao S, Fan L Y N, Lam E W F. The FOXO3-FOXM1 axis:A key cancer drug target and a modulator of cancer drug resistance[J]. Seminars in Cancer Biology, 2018, 50:77-89.
[15] Li Q, Zhang N, Jia Z L, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression[J]. Cancer Research, 2009, 69(8):3501-3509.
[16] Varghese V, Magnani L, Harada-Shoji N, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression[J]. Scientific Reports, 2019, 9(1):1505.
[17] Yang Y H, Jiang H Q, Li W X, et al. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer[J]. Aging, 2020, 12(23):24424-24440.
[18] Biller L H, Schrag D. Diagnosis and treatment of metastatic colorectal cancer:A review[J]. JAMA, 2021, 325(7):669-685.
[19] Dekker E, Tanis P J, Vleugels J L A, et al. Colorectal cancer[J]. Lancet:London, England, 2019, 394(10207):1467-1480.
[20] Sokolovi E, Ceri T, Ceri Š, et al. The Prognostic value of SUVmax of ¹⁸F-FDG PET/CT in patients with metastatic colorectal cancer[J]. Acta Medica Academica, 2020, 49(1):1-8.
[21] Kaida H, Toh U, Hayakawa M, et al. The relationship between ¹⁸F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer[J]. Nuclear Medicine Communications, 2013, 34(6):562-570.
[22] Kim D H, Song B I, Hong C M, et al. Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41(11):2051-2057.
[23] Im H J, Oo S, Jung W, et al. Prognostic value of metabolic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer[J]. Medicine, 2016, 95(19):e3686.
[24] Ogawa S, Itabashi M, Kondo C, et al. Prognostic value of total lesion glycolysis measured by ¹⁸F-FDG-PET/CT in patients with colorectal cancer[J]. Anticancer Research, 2015, 35(6):3495-3500.
[25] 丁重阳, 郭喆, 孙晋, 等. 18氟-氟代脱氧葡萄糖PET/CT检查判断胰腺癌预后的临床价值[J]. 中华消化外科杂志, 2017, 16(10):1072-1080.
[26] Xu J Y, Li Y, Hu S L, et al. The significant value of predicting prognosis in patients with colorectal cancer using (18)F-FDG PET metabolic parameters of primary tumors and hematological parameters[J]. Annals of Nuclear Medicine, 2019, 33(1):32-38.
[27] Chen S W, Chen W T L, Wu Y C, et al. Which FDG/PET parameters of the primary tumors in colon or sigmoid cancer provide the best correlation with the pathological findings?[J]. European Journal of Radiology, 2013, 82(9):e405-e410.
[28] 贾朝阳. ¹⁸F-FDG PET/CT显像在结直肠癌中的应用价值[D]. 天津:天津医科大学, 2019.
[29] Lin J Z, Wang W W, Hu T T, et al. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy[J]. Cancer Letters, 2020, 469:481-489.
[30] Ros S, Wright A J, D’Santos P, et al. Metabolic imaging detects resistance to PI3Kα inhibition mediated by persistent FOXM1 expression in ER(+) breast cancer[J]. Cancer Cell, 2020, 38(4):516-533.e9.
[31] Sun H L, Men J R, Liu H Y, et al. FOXM1 facilitates breast cancer cell stemness and migration in YAP1-dependent manner[J]. Archives of Biochemistry and Biophysics, 2020, 685:108349.
[32] Zhang S C, Zhao B S, Zhou A D, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program[J]. Cancer Cell, 2017, 31(4):591-606.e6.
[33] 袁浩, 李永平, 蒋晓飞, 等. 抑制FoxM1基因表达对甲状腺乳头状癌TPC-1细胞糖酵解途径的影响[J]. 肿瘤防治研究, 2019, 46(4):289-293.

¹⁸F-FDG PET/CT代谢参数联合血清FOXM1在诊断结直肠癌淋巴结转移中的应用

Application of ¹⁸F-FDG PET/CT Metabolic Parameters Combined with Serum FOXM1 in the Diagnosis of Lymph Node Metastasis in Colorectal Cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李浩然, 张鹏, 陈冲. 能谱CT诊断胃癌淋巴结转移的价值及影响因素分析[J]. 影像科学与光化学, 2022, 40(6): 1390-1395.
[2]	兰浩, 詹锐, 汪越, 张晓琴. 超声引导下ESP与TAP对结直肠癌根治术患者治疗效果的比较[J]. 影像科学与光化学, 2022, 40(6): 1455-1459.
[3]	高洁, 彭月享, 赵珊珊, 罗篪, 高卫元. 超声弹性成像技术联合Mts1蛋白诊断甲状腺癌的价值分析[J]. 影像科学与光化学, 2022, 40(6): 1460-1464.
[4]	张健, 任晓燕. 能谱CT联合长链非编码RNA UCA1在诊断胃腺癌淋巴结转移中的应用[J]. 影像科学与光化学, 2022, 40(6): 1539-1544.
[5]	姚玉洁, 杜春玲, 刘雅宁, 张钗. 多层螺旋CT联合miR-142-5p对宫颈癌淋巴结转移的诊断分析[J]. 影像科学与光化学, 2022, 40(4): 902-906.
[6]	甘梅香, 黎秋兰, 张晓丹. MRI在诊断舌部鳞癌致颈部淋巴结转移中的应用[J]. 影像科学与光化学, 2022, 40(4): 947-951.
[7]	张晓洁, 李娜, 杨芳, 侯倩倩, 李玲玲, 蔡红许. ¹⁸F-FDG PET/CT技术评价T2DM对晚期结直肠癌患者PD-L1治疗疗效的影响[J]. 影像科学与光化学, 2022, 40(2): 237-242.
[8]	李朝喜, 温德惠, 陆海永, 刘伟亮. 不同超声技术及TI-RADS在甲状腺癌淋巴结转移中的应用效果[J]. 影像科学与光化学, 2022, 40(2): 335-338.
[9]	蔡丽, 全祥. 增强CT联合血清指标诊断结直肠癌的价值[J]. 影像科学与光化学, 2022, 40(1): 43-47.
[10]	李小玲, 苏洁敏, 王振平. MR-DWI成像预测乳腺癌腋窝淋巴转移的价值[J]. 影像科学与光化学, 2022, 40(1): 170-174.
[11]	董军, 刘军. 超声特征对PTMC淋巴结转移诊断价值[J]. 影像科学与光化学, 2021, 39(6): 875-878.
[12]	张硕, 王淑文, 郭学敏, 徐虹, 王燕翔, 张霞, 杨莉. 三维断层超声成像联合超声造影在DTC评估中的价值[J]. 影像科学与光化学, 2021, 39(6): 896-901.
[13]	邹华玉, 周音频. CT联合高分辨率盆腔MRI扫描对结直肠癌的诊断价值[J]. 影像科学与光化学, 2021, 39(3): 479-482.
[14]	罗雄, 夏于新, 孙晓梅, 李明月, 王柯涵, 吴诚. 结肠镜联合CEA、CA242鉴别结直肠息肉与癌变的效能研究[J]. 影像科学与光化学, 2021, 39(2): 280-285.
[15]	韩茜茜, 卜岛. CT检查联合血清肿瘤标志物对宫颈癌患者腹膜后淋巴结转移的诊断价值[J]. 影像科学与光化学, 2020, 38(6): 982-987.